Cencora Inc. (NYSE:COR) on Wednesday reported its first quarter fiscal year revenue of $85.93 billion, up 5.5% year-over-year, below the Wall Street estimate of $86.03 billion.
Sales increased primarily due to a 5% increase in revenue within the U.S. Healthcare Solutions segment and a 9.6% increase in revenue within the International Healthcare Solutions segment.
The drug wholesale and distribution company reported adjusted earnings of $4.08 per share, beating the consensus of $4.03.
Gross profit was $3.1 billion, a 20.1% increase, primarily due to the increase in gross profit in both reportable segments and an increase in the LIFO credit in the current year quarter.
Gross margin was 3.58%, an increase of 44 basis …